IMR Press / JIN / Volume 22 / Issue 5 / DOI: 10.31083/j.jin2205118
Open Access Review
Research Progress in Immunotherapy of Gliomas
Show Less
1 Department of Neurosurgery, Shanghai Pudong Hospital, Pudong Hospital, Fudan University, 201399 Shanghai, China
2 School of Public Health, Fudan University, 200032 Shanghai, China
*Correspondence: (Zi-long Wei)
J. Integr. Neurosci. 2023, 22(5), 118;
Submitted: 31 January 2023 | Revised: 27 April 2023 | Accepted: 6 May 2023 | Published: 14 August 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Although some progress has been made in tumor treatment, gliomas remain one of the tumors that can still seriously threaten human life and health. Due to the particularity of the immune microenvironment of the central nervous system and the strong invasiveness of tumors, the treatment of gliomas remains a major challenge. Currently, researchers have explored a large number of immunotherapy programs to improve the survival and prognosis of glioma patients, including tumor vaccines, immune checkpoint inhibitors, adoptive cell transfer therapy, viral vector therapy, and genetic engineering therapy. The goal of these programs is to activate or change the immunosuppressive environment and target tumor cells through drugs, combined with surgical resection, radiotherapy, chemotherapy, and anti-angiogenesis drugs, to achieve the purpose of treating glioma. This review briefly describes the immunosuppressive microenvironment of gliomas and summarizes recent immunotherapeutic strategies and their progress. The aim is to summarize the latest immunotherapies for the treatment of gliomas and provide new research directions.

tumor immune microenvironment
tumor vaccines
immune checkpoint inhibitors
adoptive cell transfer therapy
viral vector therapy
PWRd2019-15/Fund of Academic Leaders Training Program of Pudong Health Committee of Shanghai
Back to top